Analysts are on the Bearish side about Teva Pharmaceutical Industries Limited (NYSE:TEVA) this week.

September 16, 2018 - By Marguerite Chambers

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 12 analysts covering Teva Pharma (NYSE:TEVA), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Teva Pharma had 16 analyst reports since March 20, 2018 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Thursday, May 31. As per Monday, May 7, the company rating was maintained by Morgan Stanley. The firm earned “Equal-Weight” rating on Monday, August 6 by Barclays Capital. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Sell” rating given on Monday, June 11 by Leerink Swann. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Equal-Weight” rating given on Thursday, May 24 by Barclays Capital. The firm earned “Hold” rating on Tuesday, March 20 by Jefferies. The company was maintained on Friday, April 20 by Mizuho. The stock has “Buy” rating by Mizuho on Monday, May 7. Wells Fargo maintained the stock with “Sell” rating in Thursday, May 3 report. Credit Suisse downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, September 7 to “Neutral” rating. Below is a list of Teva Pharmaceutical Industries Limited (NYSE:TEVA) latest ratings and price target changes.

07/09/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Neutral Old Target: $25 New Target: $23 Downgrade
06/08/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $20 New Target: $23 Maintain
03/08/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $19 New Target: $20 Maintain
16/07/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $18 New Target: $25 Maintain
25/06/2018 Broker: Goldman Sachs Rating: Buy New Target: $28.0000 Upgrade
18/06/2018 Broker: Wells Fargo Old Rating: Underperform New Rating: Market Perform Upgrade
11/06/2018 Broker: Leerink Swann Rating: Sell New Target: $16.0000 Maintain
31/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $25 Maintain
24/05/2018 Broker: Guggenheim Rating: Hold Maintain
24/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $13 New Target: $20 Maintain

The stock increased 2.88% or $0.64 during the last trading session, reaching $22.85. About 11.57 million shares traded or 13.04% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has risen 14.85% since September 16, 2017 and is uptrending. It has underperformed by 0.77% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $23.27 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Seekingalpha.com which released: “FDA OKs Teva’s opioid dependence med Cassipa” on September 07, 2018, also Seekingalpha.com with their article: “Bausch Health resolves Xifaxan patent dispute with Actavis” published on September 12, 2018, Seekingalpha.com published: “Teva +5% as migraine treatment wins FDA approval” on September 14, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on September 14, 2018 as well as Nasdaq.com‘s news article titled: “3 Top Large-Cap Stocks to Buy in September” with publication date: September 09, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>